Forty Percent of Postmenopausal Breast Cancers Preventable by Lifestyle Changes(9/5/2008) Researchers from the University of Wisconsin-Madison, the H. Lee Moffitt Cancer Center, Dartmouth Medical School, and the Fred Hutchinson Cancer Center have reported that 40.7% of postmenopausal breast cancer can be prevented by changes in lifestyle. The details of this study appeared in the August 15, 2008 issue of the American Journal of Epidemiology.
Livial® Reduces Breast Cancer Risk but Increases Stroke Risk(8/21/2008) Livial® (tibolone), an agent used to reduce menopausal symptoms as well as bone loss, significantly reduces the risk of breast cancer and prevents bone loss and fractures in older postmenopausal women; however, it doubles the risk of stroke among postmenopausal women. These results were recently published in the New England Journal of Medicine.
Ultrasound Improves Detection of Breast Cancer(5/20/2008) Researchers affiliated with the American College of Radiology Imaging Network (ACRIN) trial have reported that the addition of ultrasound to mammography significantly increases the number of breast cancers detected in high-risk women but also increases the number of false-positive tests. The details of this randomized study appeared in the May 14, 2008 issue of the Journal of the American Medical Association.
Early Life Physical Activity Decreases Risk of Premenopausal Breast Cancer(5/20/2008) Researchers affiliated with the Nurses’s Health Study II have reported that exercise in the teens and early adulthood was associated with a decreased incidence of premenopausal breast cancer. The details of this study appeared in an early online publication in the Journal of the National Cancer Institute on May 13, 2008.
Elderly Women Benefit from Screening Mammography(5/1/2008) Researchers from the M.D. Anderson Cancer Center have reported that regular mammograms among women 80 years of age and older may detect earlier stages of breast cancer. These findings were released in an early online publication of the Journal of Clinical Oncology on April 21, 2008.
Specific Gene Mutations May Affect Response to Tamoxifen in Breast Cancer(5/12/2008) Researchers from the Dana Farber Cancer Center, Brigham and Women's Hospital, and Harvard Medical School have reported that mutations within the CYP2D6 gene may affect the way in which a patient with hormone-positive breast cancer responds to tamoxifen (Nolvadex®). These results were recently published in the May 7, 2008 issue of the Journal of the National Cancer Institute.
95% of Website Breast Cancer Information Is Accurate(2/20/2008) Researchers from the University of Texas in Houston have reported that approximately 95% of information about breast cancer that is found on the Internet is accurate but current quality criteria do not detect inaccurate information especially on sites dealing with complementary or alternative medical (CAM) information. These results were recently published in the journal Cancer.
Surgery Alone May Be Not Effective Enough in High-Grade DCIS(12/20/2006) According to results presented at the 2006 San Antonio Breast Cancer Symposium (SABCS), the addition of radiation therapy reduces recurrences compared to surgery alone in women with ductal carcinoma in situ (DCIS).
‘Boost’ Radiation Reduces Cancer Recurrences for Young Women with DCIS(8/6/2006) A multicenter international clinical trial has determined that women who are 45 years or younger with ductal carcinoma in situ (DCIS) have a reduced risk of cancer recurrences if they receive an additional “boost” of radiation therapy.
Oncotype DX® Assay Compares Favorably with Immunohistochemistry for ER and PR Status of Breast Cancer(6/13/2008) Researchers affiliated with Eastern Cooperative Group (ECOG) study E2197 have reported that the reverse-transcriptase polymerase chain reaction (RT-PCR) assay, Oncotype DX®, has a high concordance with immunohistochemistry (IHC) for determination of estrogen receptor (ER) and progesterone receptor (PR) status of localized breast cancer. The details of this study were published in the May 20, 2008 issue of the Journal of Clinical Oncology.
Stellate-ganglion Block Relieves Menopausal Symptoms in Breast Cancer Survivors(5/22/2008) Researchers from the University of Illinois have reported that a stellate-ganglion block can significantly reduce severe menopausal-like side effects among women who have been treated for breast cancer. These results were recently published in an early online publication in the Lancet Oncology on May 15, 2008.
Specific Gene Mutations May Affect Response to Tamoxifen in Breast Cancer(5/12/2008) Researchers from the Dana Farber Cancer Center, Brigham and Women's Hospital, and Harvard Medical School have reported that mutations within the CYP2D6 gene may affect the way in which a patient with hormone-positive breast cancer responds to tamoxifen (Nolvadex®). These results were recently published in the May 7, 2008 issue of the Journal of the National Cancer Institute.
Intensity-modulated Radiation Therapy Decreases Radiation Dermatitis in Breast Cancer(3/20/2008) Researchers involved in a multicenter Canadian trial have reported that intensity-modulated radiation therapy (IMRT) decreases skin toxicity compared with conventional breast radiation therapy for breast cancer. The details of this randomized study were published early online on February 19, 2008 in the Journal of Clinical Oncology.
Femara® May Protect Against Breast Cancer Years After Tamoxifen(3/14/2008) Researchers involved in a multi-center trial have reported that patients with early breast cancer treated with Femara® (letrozole) at any time after completing treatment with tamoxifen (Nolvadex®) have a reduced risk of a recurrence. These findings appeared in an early online publication in the Journal of Clinical Oncology on March 10, 2008.
Patient Home
